CASE REPORT

Pneumonia caused by *Pseudomonas fluorescens*: a case report

Xiao Liu1, Lei Xiang2, Yunhong Yin3, Hao Li3, Dedong Ma3 and Yiqing Qu3*

Abstract
Background: *Pseudomonas fluorescens* (*P. fluorescens*) has been detected in respiratory samples from patients. However, no previous reports have been published about these *P. fluorescens* cultures from lung tissues.

Case presentation: Here, we report a case of pneumonia caused by *P. fluorescens*. *P. fluorescens* was identified from lung biopsy specimens for the first time in this case. According to the antibiotic susceptibility testing (AST) of *P. fluorescens*, the patient was given ciprofloxacin treatment. The temperature of the patient then returned to normal. Chest CT examination revealed improvements in pulmonary inflammation.

Conclusions: These findings suggest that the patients with pneumonia caused by *P. fluorescens* should be treated in a timely manner according to the AST results.

Keywords: *Pseudomonas fluorescens*, Pneumonia, Fever, Lung biopsy, Case report

Background

*Pseudomonas fluorescens* (*P. fluorescens*) is a ubiquitous bacterium commonly found in moist environments, such as soil, leaves, and water [1, 2]. As a Gram-negative psychrophile with an optimum growth temperature at 25–30 °C, it is also able to grow at the human body temperature of 37 °C and can present with its virulence factors [3]. *P. fluorescens* is significantly less virulent than *P. aeruginosa* and is a rare cause of invasive hospital-acquired infections, with most common site of infection being the bloodstream [4–15]. It has been isolated in respiratory samples from patients with lung transplants [16–18], ventilator-associated pneumonia (VAP) [19], cystic fibrosis (CF) [20–22] and rice-field drowning-associated pneumonia [23].

While *P. fluorescens* has been identified in human bronchoalveolar lavage fluid (BALF), sputum specimens or throat swabs, its role in pneumonia pathogenesis is unclear. It has been previously suspected of being an aetiological agent of pneumonia in several reports [19, 24–26], however, the clinical characteristics and drug susceptibility pattern of *P. fluorescens* pneumonia have rarely been reported [25].

In this case, we report a patient with pneumonia caused by *P. fluorescens*. By presenting the clinical and antibiotics susceptibility characteristics of this patient, we will provide significant value for basic and clinical research on *P. fluorescens* infection in the future.

Case presentation

A 67-year-old man was hospitalized in our hospital complaining of a 10-day history of fever, with a temperature up to 38.8 °C. He denied cough, dyspnoea, chills, shivers or chest pain. Before hospitalization, azithromycin was given orally for 5 days and intravenously for 3 days, and levofloxacin was given intravenously for 1 day. However, the patient still had a fever. He had a past medical history of tuberculosis and gastritis. He was allergic to penicillin, cephalosporin and sulfonamide. He had smoked 10 cigarettes a day for more than 20 years. He retired from an office work and had no pneumotoxic exposure.
At admission, physical examination revealed bilateral reduced breath sounds. The patient was conscious but in a poor state of mind. He was emaciated, with a BMI of 16. The remainder of his physical examination was normal. The results of routine blood examination showed that the white blood cell (WBC) count (10,180/mm$^3$ [normal range 3500–95,000/mm$^3$]) and neutrophil (NEU) count (8600/mm$^3$ [normal range 1800–6300/mm$^3$]) were elevated. The erythrocyte sedimentation rate (ESR) (58 mm/h [normal range 0–15 mm/h]) and C-reactive protein (CRP) were increased (96.7 mg/L [normal range 5–10 mg/L]). Albumin was decreased (34.8 g/L [normal range 40–50 g/L]). The chest computed tomography (CT) scan showed scattered patchy high-density nodules with blurred edges in the bilateral lungs. Pleural effusion was present on the right side (Fig. 1A, B).

Anti-mycoplasma pneumonia test and T cell spot test of tuberculosis infection (SPOT, TB) were negative. Thyroid function, rheumatism series, immunoglobulin, complement, respiratory system tumour markers, vasculitis antibodies series, and other laboratory results were normal. The rheumatism series included anti-u1RNP Ab, anti-Smith Ab, anti-SSA Ab, anti-SSB Ab, anti-ScL-70 Ab, anti-PM-SCL Ab, anti-Jo-1 Ab, anti-CENP-B Ab, anti-PCNA Ab, anti-HHT Ab, anti-ZDB Ab, anti-HTT Ab, anti-M2 Ab, ANA, anti-dsDNA Ab, ASL, RF, CRP. The respiratory system tumour markers included CEA, CYFRA21-1, SCC, PRO-GRP, CA-125, NSE. The vasculitis antibodies series included cANCA, PR3-cANCA, pANCA, MPO-pANCA, anti-GBM Ab. In addition, cultures of sputum smears were negative for bacteria, fungi or acid-fast bacilli.

After empiric combination treatment with intravenous moxifloxacin (0.4 g, qd) and meropenem (1 g, q8 h) for approximately 2 weeks, the patient still had a fever (Fig. 2). During this period, hydrotalcite (1 g, tid) was given orally, ambroxol (30 mg, bid) and lansoprazole (30 mg, qd) were also given intravenously for dissolving sputum and protecting stomach. Thymopentin was given intramuscularly (20 mg, qd) for improving immunity. On two occasions, dexamethasone (5 mg, st) was given by intravenous injection under a fever in evening. The patient was in poor nutritional status, with difficulties in sputum excretion, making him at high risk for bronchoscopy. Considering these situations, we decided to perform CT-guided lung puncture biopsy for diagnosis.

The percutaneous lung puncture biopsy was then performed under the guidance of CT. The lung tissue
pathological features displayed acute and chronic inflammation, the proliferation of alveolar cells and fibrous tissue, and the existence of multinucleated giant cells (Fig. 3A). Silver staining of the tissue showed round foreign bodies in foam cells (Fig. 3B). The identification of the organism types in lung tissue was performed by standard biochemical tests using a standard method on a Vitek 2-GN ID card (bioMerieux, Marcy l’Etoile, France). *P. fluorescens* was identified, and Vitek 2 antibiogram susceptibility testing (AST) of *P. fluorescens* was performed. The results of AST showed that *P. fluorescens* was susceptible to ceftazidime, ciprofloxacin, cefepime, amikacin, gentamicin, tobramycin, piperacillin-tazobactam, and levofloxacin. Meanwhile, the *P. fluorescens* was resistant to ampicillin, cefazolin, imipenem, sulfamethoxazole/trimethoprim, ampicillin/sulbactam, cefotetan, and ceftriaxone (Table 1). According to the susceptibility pattern, moxifloxacin and meropenem were discontinued, and ciprofloxacin (0.4 g, bid) was administered for 4 days. The patient had no fever during treatment with ciprofloxacin (Fig. 2). Then, the patient was discharged and continued to use oral ciprofloxacin.
The patient had a return visit one month later. He denied clinical symptoms. The WBC and NEU counts of his blood samples were in the normal range. Chest CT showed the absorption of the pleural effusion and the inflammatory sites in the lungs (Fig. 1C, D). Six months later, the patient returned again and bronchoscopy was performed. No bacteria, acid-fast bacilli, fungi or spores was found in the bronchial brushings and BALF specimen.

**Discussion and conclusion**

Here, we report a case of pneumonia caused by *P. fluorescens*. *P. fluorescens* was cultured from the biopsy lung tissue of this patient. Based on the AST results of *P. fluorescens*, the condition of this patient improved in response to ciprofloxacin therapy. In previous studies of *P. fluorescens*, the clinical samples included sputum, BALF or throat swabs. In contrast to previous reports, we report *P. fluorescens* cultured from lung biopsy specimens for the first time.

The roles of *P. fluorescens* in pneumonia or other respiratory diseases pathogenesis are undefined. The clinical features of *P. fluorescens*-associated pneumonia have rarely been reported [25]. In the case of a myasthenic patient [25], during recovery from a recent polymicrobial peritonitis, he developed clinical evidence of pneumonia, with sputum cultures that were positive for *P. fluorescens*. Prior to the pneumonia, this 55-year-old patient received the treatment with intravenous cefuroxime and metronidazole, and mechanical ventilation. The *P. fluorescens* was sensitive to amikacin, gentamicin, tobramycin, netilmicin, piperacillin, ticarcillin, latamoxef and ceftazidime. He recovered after the therapy of metronidazole supplemented with intravenous ceftazidime. *P. fluorescens* was also mentioned in the aetiology of community-acquired pneumonia in a single case, and the *P. fluorescens* did not respond to therapy with ceftriaxone, but the clinical details were lacking [26].

In most previous studies, it is unclear whether the positive sputum or BALF culture results reflected acute infection or benign colonization of patients. Using amplification of bacterial 16S rRNA genes, *P. fluorescens* and other bacteria was detected in the BALF acquired from a single patient with VAP [19]. In another study of over 1,000 respiratory cultures acquired from patients with CF, the authors identified *P. fluorescens* in approximately 2% of samples and considered the organism a colonizer rather than an acute pathogen [22]. *P. fluorescens* was also identified in a single patient with CF and new lower airways infection [20]. In a survey of lung transplant recipients, *P. fluorescens* was frequently identified in BALF samples of asymptomatic recipients by pyrosequencing, but not detected via standard bacterial culture [18].

In their survey [18], researchers also searched the database of bacterial culture isolates from the University of Michigan Clinical Microbiology Laboratory. Over an 11-year period, *P. fluorescens* was cultured from over 240 distinct respiratory specimens, including sputum, throat swabs, and bronchoscopically-obtained specimens (BALF or brushings). Among patients with positive *P. fluorescens* respiratory cultures, the most common underlying pulmonary condition was CF (38.8% of all isolates), followed by other chronic airway diseases (COPD, asthma, and non-CF bronchiectasis [16.1%]) and lung transplantation (7.4%). In addition, 26 of these specimens were obtained from patients with suspected acute pneumonia, and 22 of these patients were chronically immunosuppressed or had recent healthcare exposures meeting criteria for healthcare-associated pneumonia.

In our report, the patient had none known risk factor for *P. fluorescens* colonization or infection, including ventilator usage, lung transplantation, CF, immunosuppression, or other chronic airway diseases. However, it is worth noting that this eldly patient was thin and had low albumin level, with a smoking history of more than 20 years. And he received the treatment with multiple antibiotics before lung biopsy.

The patient presented with a fever and radiographic lung infiltrate. Laboratory examinations revealed elevated WBC and NEU counts. He was in poor nutritional status, with difficulties in sputum excretion,

---

**Table 1** The antimicrobial susceptibility testing results of *P. fluorescens*

| Antibiotics               | MIC values (μg/ml) | Interpretation |
|---------------------------|--------------------|----------------|
| Ampicillin                | ≥ 32               | R              |
| Cefazolin                 | ≥ 64               | R              |
| Ceftazidime               | 8                  | S              |
| Ciprofloxacin             | ≤ 0.25             | S              |
| Imipenem                  | ≥ 16               | R              |
| Sulfamethoxazole/trimethoprim | 80         | R              |
| Cefepime                  | 4                  | S              |
| Amikacin                  | ≤ 2                | S              |
| Ampicillin/sulbactam      | ≥ 32               | R              |
| Cefotetan                 | ≥ 64               | R              |
| Ceftiraxone               | ≥ 64               | R              |
| Gentamicin                | ≤ 1                | S              |
| Tobramycin                | ≤ 1                | S              |
| Piperacillin-tazobactam   | ≤ 4                | S              |
| Levofloxacin              | 0.5                | S              |

Susceptibility cards were inoculated and interpreted according to the Clinical and Laboratory Standards Institute (CLSI) breakpoints. *P. fluorescens* Pseudomonas fluorescens, MIC minimum inhibitory concentration, R resistant, S sensitive.
making him at high risk for bronchoscopy. Therefore, the CT-guided lung puncture biopsy was performed for diagnosis. *P. fluorescens* was cultured from lung biopsy specimens. The clinical symptoms, CT and laboratory test results, pathologic findings, and treatment response to ciprofloxacin provide evidence of *P. fluorescens* infection in our case. The pathohistological diagnosis of the biopsy provided meaning guidance for a clinical diagnosis, including the exclusion of tumours, granulomatous diseases, TB infection, fungal infection, etc. However, pathological observation cannot identify the type of bacterial pathogens. More importantly, the results of tissue culture and drug sensitivity tests played an important role in guiding the use of antibiotics to treat this patient.

In the AST, *P. fluorescens* was resistant to multiple antibiotics, which may be the reason for the poor efficacy of initial empirical therapy. Notably, the antimicrobial susceptibility results of our *P. fluorescens* isolates were in agreement with known findings as described above [25, 26]. They were resistant to ceftriaxone, and sensitive to amikacin, gentamicin, tobramycin, ceftazidime and piperacillin. However, the previous studies relating antimicrobial susceptibility characteristics were early and few, the coverage of antibiotics was relatively narrow. The antimicrobial susceptibility patterns of *P. fluorescens* pneumonia need to be further summarized and clarified.

In summary, *P. fluorescens* can cause acute pneumonia, with fever as the main clinical symptom. When encountering patients with pneumonia presenting with poor efficacy of empiric antibiotic treatment, we should consider the possibility of *P. fluorescens* infection. In addition, it is important to perform the bacterial culture and AST in a timely manner. Antibiotic therapy under the guidance of the *P. fluorescens* antimicrobial spectrum is significant for such patients. However, more research is needed to study the pathogenesis of *P. fluorescens* and to establish diagnostic criteria and effective treatment of these cases.

**Abbreviations**

*P. fluorescens*; *Pseudomonas fluorescens*; CF: Cystic fibrosis; VAP: Ventilator-associated pneumonia; BALF: Bronchoalveolar lavage fluid; WBC: White blood cell; NEU: Neutrophil; ESR: Erythrocyte sedimentation rate; CRP: C-reactive protein; SPOTT.B: T cell spot test of tuberculosis infection; CT: Chest computed tomography; Ab: Antibody; u1RNP: U1-ribonucleoprotein; SSA: Sjögren’s syndrome A; SSB: Sjögren’s syndrome B; SCL-70: Topoisomerase I; PM-SCL: Polymyositis-Scleroderma; CA-125: Carbohydrate antigen 125; NSE: Neuron-specific enolase; cANCA: Cytoplasmic antineutrophil cytoplasmic antibody; PRO-GRP: Pro-gastrin releasing peptide; CYFRA21-1: Cytokeratin 19 fragment antigen 21-1; SCC: Squamous cell carcinoma antigen; ACA: Anticardiolipin antibody; ANA: Anti-nuclear antibody; dsDNA: Double-stranded DNA; ASL: Anti-streptolysin O; RF: Rheumatoid factors; CRP: C-reactive protein; CE: Cardiomyembryonic antigen; CYP2A11-1: Cytokeratin 19 fragment antigen 21-1; SCC: Squamous cell carcinoma antigen; PRO-GRP: Pro-gastrin releasing peptide; CA-125: Carbohydrate antigen 125; NSE: Neuron-specific enolase; cANCA: Cytoplasmic anti-neutrophil cytoplasmic antibody; PR3: Proteinase-3; pANCA: Perinuclear anti-neutrophil cytoplasmic antibody; MPO: Myeloperoxidase; GBM: Glomerular basement membrane; COPD: Chronic obstructive pulmonary disease.

**Acknowledgements**

Not applicable.

**Authors’ contributions**

YQ conceived and designed the work. XL integrated the data and wrote the manuscript. LX performed the histological examination of the lung tissue. YY collected the CT images of the case. HL, DM and YQ critically revised the manuscript. All authors read and approved the final manuscript.

**Funding**

Not applicable.

**Availability of data and materials**

Not applicable.

**Declarations**

**Ethics approval and consent to participate**

Written informed consent was obtained from the patient for publication of this case report and accompanying images.

**Consent for publication**

Written informed consent for publication was obtained from the participant.

**Competing interests**

The authors declare that they have no competing interests.

**Author details**

1. Department of Pulmonary and Critical Care Medicine, Qilu Hospital, Cheeloo College of Medicine, Shandong University, Jinan 250012, China. 2. Department of Pathology, School of Basic Medical Sciences, Cheeloo College of Medicine, Shandong University, Jinan 250012, China. 3. Department of Pulmonary and Critical Care Medicine, Qilu Hospital of Shandong University, Wenhuaixi Road 1074, Jinan 250012, China.

**Received:** 12 January 2021  **Accepted:** 23 June 2021  **Published online:** 05 July 2021

**References**

1. Silby MW, Cerdeño-Tárraga AM, Vernikos GS, Giddens SR, Jackson RW, Preston GM, et al. Genomic and genetic analyses of diversity and plant interactions of *Pseudomonas fluorescens*. Genome Biol. 2009;10(5):R51.
2. Feazel LM, Baumgartner LK, Peterson KL, Frank DN, Harris JK, Pace NR. Opportunistic pathogens enriched in showerhead biofilms. PLoS Natl Acad Sci USA. 2009;106(38):16393–9.
3. Scales BS, Dickson RP, LiPuma JJ, Huffnagle GB. Microbiology, genomics, and clinical significance of the *Pseudomonas fluorescens* species complex, an unappreciated colonizer of humans. Clin Microbiol Rev. 2014;27(4):927–48.
4. Gibaud M, Martin-Dupont P, Dominguez M, Laurentjoye P, Chasaing B, Leng B. *Pseudomonas fluorescens* septicemia following transfusion of contaminated blood. Presse Med (Paris, France: 1983). 1984;13(42):2583–4.
5. Hsieh PR, Teng LJ, Pan HJ, Chen YC, Sun CC, Ho SW, et al. Outbreak of *Pseudomonas fluorescens* bacteremia among oncology patients. J Clin Microbiol. 1998;36(10):2914–7.
6. Khbazz BF, Arnow PM, Highsmith AK, Herwaldt LA, Chou T, Jarvis WR, et al. *Pseudomonas fluorescens* bacteremia from blood transfusion. Am J Med. 1984;76(1):62–8.
7. Murray AE, Bartozkas CA, Shepherd AJ, Roberts FM. Blood transfusion-associated *Pseudomonas fluorescens* septicemia: is this an increasing problem? J Hosp Infect. 1987;9(3):243–8.
8. Scott J, Boulton FE, Govan JR, Miles RS, McClelland DB, Prowse CV. A fatal transfusion reaction associated with blood contaminated with *Pseudomonas fluorescens*. Vox Sang. 1988;54(4):201–4.
9. Benito N, Mirelis B, Luz Gálvez M, Villa M, López-Contreras J, Cotura A, et al. Outbreak of *Pseudomonas fluorescens* bloodstream infection in a coronary care unit. J Hosp Infect. 2012;82(4):286–9.
10. Pseudomonas bloodstream infections associated with a heparin/saline flush—Missouri, New York, Texas, and Michigan, 2004–2005. MMWR Morb Mortal Wkly Rep. 2005;54(11):269–72.
11. Update: Delayed onset Pseudomonas fluorescens bloodstream infections after exposure to contaminated heparin flush—Michigan and South Dakota, 2005–2006. MMWR Morb Mortal Wkly Rep. 2006;55(35):961–3.
12. Gershman MD, Kennedy DJ, Noble-Wang J, Kim C, Gullion J, Kacica M, et al. Multistate outbreak of Pseudomonas fluorescens bloodstream infection after exposure to contaminated heparinized saline flush prepared by a compounding pharmacy. Clin Inf Dis. 2008;47(11):1372–9.
13. Sarubbi FA Jr, Wilson B, Lee M, Brockopp C. Nosocomial meningitis and bacteremia due to contaminated amphotericin B. JAMA. 1978;239(5):416–8.
14. Arega B, Wolde-Amanuel Y, Adane K, Belay E, Abubeker A, Asrat D. Rare bacterial isolates causing bloodstream infections in Ethiopian patients with cancer. Inf Agents Cancer. 2017;12:40.
15. Shah SS, Kagen J, Lautenbach E, Bilker WB, Matro J, Dominguez TE, et al. Bloodstream infections after median sternotomy at a children’s hospital. J Thorac Cardiovasc Surg. 2007;133(2):435–40.
16. Dickson RP, Erb-Downward JR, Prescott HC, Martinez FJ, Curtis JL, Lama VN, et al. Analysis of culture-dependent versus culture-independent techniques for identification of bacteria in clinically obtained bronchoalveolar lavage fluid. J Clin Microbiol. 2014;52(10):3605–13.
17. Dickson RP, Erb-Downward JR, Freeman CM, Walker N, Scales BS, Beck JM, et al. Changes in the lung microbiome following lung transplantation include the emergence of two distinct Pseudomonas species with distinct clinical associations. PLoS ONE. 2014;9(5):e97214.
18. Bahrami-Mougeot FK, Paster BJ, Coleman S, Barbuto S, Brennan MT, Noll J, et al. Molecular analysis of oral and respiratory bacterial species associated with ventilator-associated pneumonia. J Clin Microbiol. 2007;45(5):1588–93.
19. Heirali A, McKeon S, Purighalla S, Storey DG, Rossi L, Costilhes G, et al. Assessment of the microbial constituents of the home environment of individuals with cystic fibrosis (CF) and their association with lower airways infections. PLoS ONE. 2016;11(2):e0148534.
20. Scales BS, Erb-Downward JR, Huffnagle IM, LiPuma JJ, Huffnagle GB. Comparative genomics of Pseudomonas fluorescens subclade III strains from human lungs. BMC Genom. 2015;16:1032.
21. Klinger JD, Thomassen MJ. Occurrence and antimicrobial susceptibility of gram-negative nonfermentative bacilli in cystic fibrosis patients. Diagn Microbiol Inf Dis. 1985;3(2):149–58.
22. Yamawaki S, Nakashima K, Suzuki F, Otsuki A, Watanabe J, Takai M, et al. Rice-field drowning-associated pneumonia in which Pseudomonas spp., Aspergillus fumigatus, and Cunninghamella sp. are isolated. Internal Med (Tokyo, Japan). 2016;55(7):825–9.
23. McWalter PW. Pseudomonas fluorescens cross-infection due to contaminated humidifier water. Br Med J. 1980;281(6235):275.
24. Redding PJ, McWalter PW. Pseudomonas fluorescens cross-infection due to contaminated humidifier water. Br Med J. 1980;281(6235):275.
25. Thangkhiew I. Successful treatment with ceftazidime of a Pseudomonas fluorescens chest infection in a myasthenic patient. J Antimicrob Chemother. 1986;18(3):428–9.
26. Zervos M, Nelson M. Cefepime versus ceftriaxone for empiric treatment of hospitalized patients with community-acquired pneumonia. The Cefepime Study Group. Antimicrob Agents Chemotherapy. 1998;42(4):729–33.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.